About: Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 03 September 2009

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2009 (fr) наукова стаття, опублікована у вересні 2009 (uk) im September 2009 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 03 September 2009 (en) artículu científicu espublizáu en setiembre de 2009 (ast)
publication date	wds:Q57752076-5D4E3144-FEC0-42BA-A9AD-CF16A9F6715C
publication date	2009-09-03 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57752076-E4EA49E6-7223-4460-A42C-477152DD4A49
language of work or name	English
cites work	wds:Q57752076-04F9DB90-A906-4E40-B9E7-4316069CE967 wds:Q57752076-1A8739EE-22C4-4BBF-81B6-413FE4576B84 wds:Q57752076-3171BA24-399C-4A8A-A55F-387E26FDF109 wds:Q57752076-386525CF-FCF4-4106-B4C8-55DA23C2C7F9 wds:Q57752076-3CFFE469-7B44-4EA0-9419-F3E3175E688D wds:Q57752076-47662FD7-0424-4C7A-B12C-30CF77806AB2 wds:Q57752076-54A2AF74-BAD3-46FD-89BF-53BA4D323F30 wds:Q57752076-5583EE9D-EC60-4CCB-8BA8-6914A41FC215 wds:Q57752076-8F30C0A3-6F9F-498A-8C6D-004068908353 wds:Q57752076-AD82AD25-7866-4929-937A-382216B3138C wds:Q57752076-B1BBB242-BA50-422F-A10D-FAFC217C421E wds:Q57752076-E68BFC28-C60B-4D51-A387-D0C62D52DD55 wds:Q57752076-ECFD800F-B833-4B69-8BE4-AEB26F98CAF8 wds:Q57752076-EF921E93-1A0A-4C88-A5FC-D02D8FD26F19
cites work	Mechanisms of Disease: the link between RANKL and arthritic bone disease Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial Sustained response to intravenous alendronate in postmenopausal osteoporosis Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Effects of rheumatoid arthritis on bone Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts?
author name string	wds:Q57752076-12B88124-1405-4E37-813A-8AC2FFF6038F wds:Q57752076-2BEAAAC4-9A39-4428-9BDF-84C38FE3E8A6 wds:Q57752076-441264EE-FB72-44BB-A51B-DE5852C82728 wds:Q57752076-5DDD759C-95B9-49F0-85AB-910D6981EFF3 wds:Q57752076-7B82745D-519F-49DD-93B0-F1F464C2D073 wds:Q57752076-7D281867-7D4D-4A6D-A5ED-2A6A98DB95BD wds:Q57752076-A0A9C718-4C22-45C6-AB93-D4D903B7D78E wds:Q57752076-CC88350D-7E28-45A5-9C05-B4161E3A555D wds:Q57752076-ECD7DDC1-2165-4415-A18E-06DBBCB85A86
author name string	Nancy E Lane William Palmer Robin K Dore Huei Wang Richard Newmark Wayne Tsuji Lifen Zhou William Shergy Denosumab RA Study Group
rdfs:label	Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (en) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (nl)
skos:prefLabel	Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (en) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (nl)
name	Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (en) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (nl)
author	wds:Q57752076-74BCF50C-78D5-42BE-AB1F-9286F5822D9E
author	Stanley B Cohen
title	wds:Q57752076-2EAA71BD-82ED-400A-B57A-2BD5D085E065
title	Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates (en)
page(s)	wds:Q57752076-975EDA6E-B514-4FF8-931A-FDC193C7FFD4
page(s)	872-875
instance of	wds:Q57752076-F8F5FB3D-1D1F-4BBC-AC09-121444AA961D
instance of	scholarly article
main subject	wds:Q57752076-0CEF3BF8-7A1B-45C6-894A-78CDE754DB63 wds:Q57752076-27D983BB-A85B-48EC-AC9D-4C78C9A57E7C
main subject	rheumatoid arthritis Patients
PubMed ID	wds:Q57752076-F888A77E-DA56-4C4A-A4E1-779A37DF99C6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19734132
PubMed ID	19734132
published in	wds:Q57752076-AC92D961-EEB8-4741-9104-BFF8CAFABB2B
published in	Annals of the Rheumatic Diseases
issue	wds:Q57752076-C962D5AF-8E74-44DB-ACCE-37BEB3DF2D24
volume	wds:Q57752076-DC0B8D75-8A12-4F77-B072-F49155A84F89
issue	5
volume	69
DOI	wds:Q57752076-378BC6F7-52F6-417C-BC46-7FFD27F04435
DOI	http://dx.doi.org/10.1136/ARD.2009.112920
DOI	10.1136/ARD.2009.112920
PMCID	wds:Q57752076-30AFD488-3224-4457-8489-623BBC3D0EBB
PMCID	6909937
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57752076
is cites work of	Inflammatory bone loss: pathogenesis and therapeutic intervention Management of glucocorticoid-induced osteoporosis. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases Osteoimmunology and osteoporosis Clinical utility of denosumab for treatment of bone loss in men and women Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways Glucocorticoid-induced osteoporosis The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions Therapeutic targeting of osteoclast function and pathways.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software